BOULDER, Colo., June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has closed its underwritten public offering of 9,920,987 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,526,250 additional shares of its common stock, at a price to the public of $19.66 per share and, i ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced underwritten public offering of 8,394,737 shares of its common stock at a price to the public of $19.66 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,780,263 sha ...

BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has commenced an underwritten public offering of $200 million of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven's common stock. In addition, Enliven intends to grant the u ...

Company Overview - Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics aimed at improving both longevity and quality of life [3] - The company employs a precision oncology approach to address existing and emerging unmet medical needs, enhancing survival and overall well-being [3] - Enliven's discovery process integrates insights from clinically validated biological targets with differentiated chemistry to create potentially first-in-class or best-in-class therapies [3] Upcoming Events - Enliven will present at the TD Cowen's 6th Annual Oncology Innovation Summit on May 27, 2025, at 1:00 p.m. ET in a fireside chat format [1] - The company will also participate in the Jefferies Global Healthcare Conference on June 4, 2025, at 4:20 p.m. ET, again in a fireside chat format [1] - Additionally, Enliven is scheduled to present at the Goldman Sachs Annual Global Healthcare Conference on June 10, 2025, at 4:00 p.m. ET [2] - All fireside chats will be webcast live and archived for 90 days on the company's investor relations website [2]